

Phosphodiesterases Inhibition by Bacilli Calmette-Guérin Contributes to Decrease Asthma in Allergic Rats

Yajuan Wang^{1,2}, Yali Jiang¹, Huifang Tang¹, Xuefeng Wang¹, Chunzhen Zhao¹, and Jiqiang Chen¹

¹ Zhejiang Respiratory Drugs Research Laboratory of State Food and Drug Administration of China, College of Medicine, Zhejiang University, Hangzhou 310058, China

² The Center of Function Experiment, Anhui College of Traditional Chinese Medicine, Hefei, 230038, China

³ The Pharmacy Department of The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310058, China

Received: 5 December 2011 ; Received in revised form: 16 March 2011 ; Accepted: 18 March 2011

ABSTRACT

Phosphodiesterases (PDE) hydrolyse intracellular cAMP and cGMP to inactive 5' monophosphates. Decreased level of cAMP is involved in the pathogenesis of asthma. We and others have shown that phosphodiesterases were upregulated in the lung of allergic rats, and Bacilli Calmette-Guérin (BCG) induced the production of cAMP *in vitro*. However, it is unclear how BCG's effect asthma and whether it is related to PDEs.

In this study, BCG was intraperitoneally injected into male Sprague-Dawley rats sensitized and later the rats were challenged with ovabumin/pertusis. The inflammation in lungs was measured. Airway hyperresponsiveness was determined using MedLab software after intravenous methacholine challenge. Furthermore, cAMP level and adenylate cyclase activity in lungs were analyzed by ELISA, phosphodiesterases activities were analyzed by HPLC, while PDEs mRNA levels in lungs was analyzed by reverse transcription-polymerase chain reaction. Administration of BCG significantly attenuated allergen-induced lung inflammatory response and hyper responsiveness as compared with vehicle treatment. Furthermore, the levels of cAMP in lungs were significantly increased in BCG-treated allergic rats. Interestingly, administration of BCG decreased the activity of cAMP-PDE, but not adenylate cyclase (AC), activity in lungs of animals. Furthermore, pretreatment with BCG significantly decreased the mRNA levels of PDE4A, 4C, 5 and 8, which were induced in lungs of allergic rats.

BCG administration attenuated airway inflammatory response and bronchial hyper responsiveness in rats, which are the most important symptoms in asthma. The decreased PDEs mRNA and inhibited cAMP-PDE activities by BCG contribute, at least in part, prevention of allergen-induced airway inflammation and asthma in rats.

Key words: Adenylate Cyclase; Asthma; Bacillus Calmette-Guérin; cAMP; Phosphodiesterase

Corresponding Author: Ji-qiang Chen, MD;

Zhejiang Respiratory Drugs Research, Laboratory of State Food and Drug Administration of China, College of Medicine, Zhejiang University, Hangzhou 310058, China. Tel: (+86 571) 88208232, Fax: (+86 571) 88208232, E-mail: chenjq@zju.edu.cn

INTRODUCTION

Asthma is a chronic inflammatory condition that causes the airways to constrict and produce excess

mucus, making breathing difficult. It is characterized by airway inflammation and hyperresponsiveness, and is associated with significant yet avoidable mortality and morbidity resulting in considerable individual and societal burden.^{1,2} The hallmark of asthma is airway inflammation.³ Airway obstruction in asthma can be severe, leading to life-threatening narrowing and closure of airways.⁴ Inflammatory cellular infiltration, particularly by eosinophils (and in some cases, neutrophils), plays an important role in airway inflammation in asthma, and this may be attributed to the production of T helper cell Th2 cytokines.⁵ Long-term control medications in patients with asthma mainly include corticosteroids, cromolyn sodium and nedocromil, methylxanthines, leukotriene modifiers, and long-acting beta2-agonists (LABAs). Inhaled corticosteroids (ICS), short- and long-acting β_2 -adrenoceptor agonists are now the mainstay therapy for asthma. ICS are the most effective class of controller medication available for treating persistent asthma, and are the evidence-based guideline-recommended first-line treatment for control asthma.² ICS is highly effective in suppressing airway inflammation. β_2 -adrenoceptor agonists act primarily to relax airway smooth muscle by stimulating beta2-receptors, which in turn increase cyclic AMP and produce functional antagonism to bronchoconstriction. However, both ICS and β_2 -adrenoceptor agonists do not influence the natural history of the disease, even though treatment is started early in childhood.^{6,7} Therefore, it is urgent to find new drugs with more efficiency to intervene the development of asthma. Phosphodiesterases (PDEs) are important enzymes in the hydrolysis of cAMP and cGMP to inactivate nucleotides.⁸ Inhibition of PDEs elevates the levels of cAMP and cGMP, which regulates a variety of cellular functions including airway smooth muscle relaxation and reduction of cellular inflammation as well as immune responses. Decreased cAMP is a contributing factor in pathogenesis of asthma.⁹⁻¹¹ Therefore, many drugs which can induce cAMP production are used in asthma treatment, e.g. β_2 -adrenoceptor agonists and theophylline.^{12,13} It has been shown that a large number of extracellular stimuli can induce intracellular cAMP production by activating adenylyl cyclase (AC) or inhibiting PDEs. Therefore, the agents regulate AC and PDEs activities may be beneficial in attenuating the progression of asthma. Indeed, cAMP-elevating agents, such as PDE4 inhibitor, significantly decrease airway

inflammation and hyperresponsiveness via inhibiting Th2 cell function and pro-inflammatory mediators release.¹⁴⁻¹⁷ Bacillus Calmette-Guérin (or Bacille Calmette-Guérin, BCG) is a bacterial vaccine against tuberculosis that is prepared from a strain of the attenuated live bovine tuberculosis bacillus, *Mycobacterium bovis*, that has lost its virulence in humans. However, the bacilli have retained enough strong antigenicity to become a somewhat effective vaccine for the prevention of human tuberculosis. There is increasing, but still inconsistent evidence that BCG vaccinations is associated with the normal maturation of the immune system.^{18,19} Furthermore, the positive tuberculin reactivity was inversely associated with the prevalence of wheeze, asthma and atopic eczema, especially among Japanese children without a parental allergic history.²⁰ These findings support the hygiene hypothesis of asthma²¹ (e.g., the beneficial effects against children infections and BCG vaccinations on asthma).²²⁻²⁴ Although there is no comparison between the prevalence of asthma in countries which inoculate BCG routinely and that in countries which do not, indeed, BCG is a strong inducer of T-helper type 1 immune response (Th1) and modulates the development of asthma both in animal models and human beings.²⁵ BCG infection is known to induce various cytokines, and to inhibit allergen-specific IgE production, ovalbumin (OVA)-induced eosinophilia as well as goblet cell development.²⁶⁻²⁹ Accumulating evidence shows that BCG downregulates OVA-induced eosinophilia and specific IgE production via inhibiting Th2 cytokines and enhancing Th1 cytokines.^{30,31} BCG could inhibit methacholine (MCh) induced airway hyperresponsiveness (AHR) in mice^{32,33} and inhibit airway responsiveness.^{34,35} Nevertheless, the molecular mechanism in BCG for attenuating allergens-induced airway inflammatory response is unknown. Recent study showed that BCG induced the production of cAMP, and the regulation of IL-6 by BCG is via a cAMP-dependent pathway in human bladder cancer cells.³⁶ Therefore, we hypothesize that BCG protects against allergen-induced asthmatic response in rats via a cAMP-dependent pathway, that is, by regulating PDEs. To test this hypothesis, BCG was intraperitoneally administrated to OVA-sensitized and -challenged Sprague-Dawley (SD) rats, and the airway inflammation and airway hyperresponsiveness were determined. We also investigated the effect of BCG on cAMP levels, AC activity, PDE activity as

well as PDEs mRNA levels in ovalbumin (OVA)-challenged asthmatic model of rats.

MATERIALS AND METHODS

Allergen Sensitization and Challenge in Rats

Six-week-old male Sprague-Dawley (SD) rats were purchased from Laboratory Animal Center of Zhejiang Chinese Medicine University (Hangzhou, China). All animals were housed in a room maintained at $23 \pm 2^\circ\text{C}$ with $50\% \pm 10\%$ humidity and a 12 h light 12 h dark cycle (lights on from 8:00 a.m. to 8:00 p.m.). Animals were allowed free access to tap water and regular rodent chow. Rodent chow was withheld for 8 h before the experiments. All the animal care and handling procedures were approved by the Institutional Animal Care and Use Committee of Zhejiang University. Rats were sensitized with a subcutaneous injection (1 ml/rat) of a saline suspension containing 0.2% OVA (Sigma, St. Louis, MO) and 10% aluminum hydroxide at their footpad, neck, back, groin, and abdomen on day 0 according to the previous publications.^{37,38} At same day, each animal was primed with an intramuscular injection of 2×10^{10} heat-inactivated *bordatella pertussis* organisms (Biological Institute of Shanghai, Shanghai, China). From day 14 after sensitization, animals were challenged once a day for 7 days by exposure for 30 minutes to aerosolized OVA (1%) in saline generated by a jet nebulizer (Master; Pari GmbH, Starnberg, Germany; medium diameter of produced droplets: 1-5 μm) (Figure 1).

Animal Grouping and Treatment

Rats were divided into four groups with 6 rats in each group. Control group animals were sensitized and challenged with saline; model group animals were sensitized with OVA and pertussis, and challenged with OVA; BCG group animals were sensitized and challenged as the same to model group, but were administered also with BCG (3×10^6 U/rat) (D2-BP302 strain, (Biological Institute of Shanghai, Shanghai, China) intraperitoneally once a day at days 0 and days 5, as described previously.³⁹ In dexamethasone-treated animals, allergen sensitization and challenge were the same as that in model group, but dexamethasone (Zhejiang Xianju Pharmaceuticals Co., LTD, Hangzhou, China) was administered intraperitoneally once a day at day 0 and day 5 with a dose of 1 mg/kg. The doses of BCG and dexamethasone were adopted in the present study based on our preliminary results and previous studies.^{37,38} We chose dexamethasone as control because bronchial asthma, including its mild forms, are chronic inflammatory diseases of bronchial tubes, requiring application of anti-inflammatory therapy, foremost the use corticosteroids, which are capable to improve considerably prognosis for such patients.⁴⁰ Dexamethasone was highly effective in suppressing airway inflammation according to our previous study,^{37,38} and we wanted to compare the efficacy of BCG together with dexamethasone in inflammation and lung function when we did not know the exact mechanism of BCG. At day 21, animals were sacrificed, and lung tissues were removed and frozen in liquid nitrogen, and then stored at -80°C , until analysis.




Figure 1. Procedure of asthma model of SD rats.

Preparation of Bronchoalveolar Lavage Fluids (BALF) for Cell Counting and Differentiation

At 24 h after the last OVA challenge, rats were anesthetized with urethane (1 g/kg, i.p.), and lungs were three times lavaged with 5 ml of sterilized normal saline containing 1% bovine serum albumin (BSA) and 5000 IU/l heparin. BALF was combined and centrifuged at 500 ×g at 4 °C for 10 min. The pellets were resuspended with Hank's balanced salt solution (HBSS) for cell counts and classification. Two hundred cells from the cell suspension were stained by Wright-Giemsa and differentiated under light microscope. The results are expressed as the numbers of each type of cell population per one liter of BALF.

Measurement of Airway Hyperresponsiveness

Airway resistance (R_L) and dynamic compliance (C_{dyn}) were determined as changes of airway function after intravenous injection of methacholine (MCh).⁴¹ Briefly, each anesthetized rat was placed supine inside a plexiglas whole-body plethysmograph. The expiratory flow rate was monitored with a fisher tube connected to the airway in a pressure transducer, and the change in lung volume was measured by detecting pressure changes in the plethysmographic chamber through a port in the connecting tube with a pressure transducer. To measure pleural pressure, a needle with a multiholed tip was directly inserted into pleural cavity through a port in the connecting tube with a differential pressure transducer. Transpulmonary pressure was calculated as the difference between mouth and pleural pressure. The signals from all pressure transducers were continuously processed (MedLab, Nanjing Biotech Instruments, Nanjing, China) by fitting flow, volume, and pressure to an equation of motion. Changes in R_L and C_{dyn} from MCh provocation were shown by using a dose-response curve. MCh dosages (0.4g/L to 8g/L, i.v.) were decided from the pre-trial (those could provoke airway hyperreaction in rats and did not cause death). The effects of BCG and dexamethasone were determined by comparing the changes in R_L and C_{dyn} after drug treatment with the mean of MCh response alone in the same rat on previous and successive control periods.

Assay for IL-4 and IFN- γ in Lung Tissue

Fifty milligrams of lung tissues were homogenized in 1 ml of ice-cold 50 mM Tris-Maleate buffer (pH=7.4, containing 5 mM $MgSO_4$). The assay mixture was cooled on ice, followed by centrifugation at

12,000×g for 30 minutes at 4 °C. The amount of IL-4 and IFN- γ present in the supernatant was determined using a rat IL-4-specific ELISA kit (KRC0041, Biosource) and a rat IFN- γ -specific ELISA kit (BMS621, Bender MedSystems), respectively. For IL-4 assay kit, the inter-assay and intra-assay coefficients of variation were 7.8% and 2.9%, respectively. For IFN- γ assay kit, the inter-assay and intra-assay coefficients of variation were 9.0% and 8.0%, respectively.

Histological Examination

The lungs were immersed in 10% neutral formalin for 7 days. After tissues were paraffinized, 5 μ m sections were prepared and stained with hematoxylin-eosin for observation of inflammatory cell infiltration under light microscope.

Assay for cAMP in Lung Tissue

Fifty milligrams of lung tissues were homogenized in 1 ml of ice-cold 50 mM Tris-Maleate buffer (pH=7.4, containing 5 mM $MgSO_4$), the assay mixture was cooled on ice, followed by centrifugation at 12,000×g for 30 minutes at 4 °C. The amount of cAMP present in the supernatant was determined by cAMP ELISA kit (R&D Systems, Inc., Minneapolis, USA). For this cAMP assay kit, the inter-assay and intra-assay coefficients of variation were 7.6% and 4.2%, respectively.

Assay for AC Activity

AC activity was measured as described previously.⁴² Briefly, the AC assay mixture (500 μ l) contained 50 mM Tris-Maleate buffer, 8 mM theophylline, 4 mM DTT, 1 mM EGTA, and 1 mM ATP. The AC reaction was started by the addition of 100 μ l lung homogenate into 500 μ l of AC assay mixture, and was performed at 30 °C for 15 minutes. The reaction was stopped by boiling the mixture for 3 minutes. The assay mixture was cooled on ice, followed by centrifugation at 4 °C. The amount of cAMP present in the supernatant was determined by cAMP ELISA kit (R&D).

Assay for cAMP-PDE Activity

Twenty-five milligrams of lung tissues were homogenized in 1 ml of ice-cold 30 mM N-2-hydroxyethylpiperazine- N'-ethane sulfonic acid (pH =7.4) containing 0.1% Trion X-100 (Sigma). The cAMP-PDE assay mixture (200 μ l) in phosphate-buffered saline (pH= 7.4) contained 137 mM NaCl, 2.7

mM KCl, 8.8 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 1 mM CaCl₂, 1 mM MgCl₂, and 1 μM cAMP (Sigma). The PDE reaction was started by the addition of 20 μl lung homogenate into 200 μl of cAMP-PDE assay mixture, and was performed at 37°C for 30 minutes. The reaction was stopped by boiling the mixture for 3 minutes. The assay mixture was cooled on ice, followed by centrifugation at 12,850×g for 30 minutes at 4 °C. The amount of cAMP present in the supernatant was determined by HPLC (Agilent TC-C18 4.6×250 mm; Hewlett-Packard, Palo Alto, CA) by using a standard curve of cAMP.³⁸

Assay for PDEs mRNA Expressions in Rat Lungs

Total RNA was isolated from each tissue using Trizol reagent (Sigma). The preparation of first-strand complementary DNA (cDNA) from total RNA was performed using a first-strand cDNA synthesis kit (Shanghai Sangon Biological Engineering Technology and Service Co. Ltd., Shanghai, China). Sequences of polymerase chain reaction (PCR) primer sets used for PDEs and internal standard. β-actin were described previously and listed in table 1.⁴³⁻⁴⁶ PCR amplification was performed in a reaction buffer (10 mM Tris-HCl, pH 9.0; 100 mM KCl; 80 mM [NH₄]₂SO₄; and 0.1% Nonidet P-40) containing 0.2 mM each nucleotide, 1.5 mM MgCl₂, 500 nM each primer, and 1 U of Taq DNA polymerase (Sangon) in a total volume of 25 μl, and PCR was performed for 35 cycles. After amplification, 8 μl of each reaction mixture was resolved by electrophoresis on a 1.5% agarose gel containing ethidium bromide, and the PCR product bands were quantified by using the UVP Gel Documentation system (UVP, Upland, CA). The levels of PDEs mRNAs were calculated relative to β-actin.

Assay for Total Protein

The amounts of total protein were determined by the Bradford method using a coomassie blue staining protein assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Bovine serum albumin was used as the standard.

Statistical Analysis

Data are expressed as means ± SD. Statistical analysis was performed with a one-way ANOVA to evaluate the levels of cAMP-PDE activity, AC activity, cAMP, IL-4 and IFN-γ, a nonparametric test to evaluate pulmonary functions, and a student two-tailed t-test to calculate the inflammatory cells and evaluate the PDE4 mRNA expression. Significance was assessed at the *P* < 0.05 level. Experiments were performed independently for at least twice. Results were qualitatively identical, and representative results are shown.

RESULTS

Effect of BCG on Allergen-induced Inflammatory Cell Infiltration in Lungs

Male SD rats were sensitized and challenged with OVA to induce lung inflammation. Lungs were lavaged at 24 h post-last OVA challenge, and differential cells in BALF were counted to investigate the effect of BCG on inflammatory cells influx. We found that the total number of cells in BALF of OVA-vehicle rats was 5-fold greater than that in NS-vehicle rats (NS control: 35.0×10⁸ cells/L). BCG treatment significantly decreased the number of total cells in BALF, which was slightly more than that in dexamethasone-treated rats (Figure 2A).

Table 1. Primer sequences used in this study

| Gene | Primer sequences(5'-3') | Length of PCR product (bp) | Tm (°C) |
|---------|------------------------------------|----------------------------|---------|
| β-actin | Sense: AACCCCTAAGGCCAACCGTGAAAAG | 343 | 57 |
| | Antisense: GCTCGAAGTCTAGGGCAACATA | | |
| PDE4A | Sense: TCAACACCAATTCGGAGCTGG | 216 | 61 |
| | Antisense: GTCTTCAGGTCAGCCAGGAGG | | |
| PDE4C | Sense: ACTGAGTCTGCGCAGGATGG | 539 | 62 |
| | Antisense: ACTCCTCTTCCTCTGCTCTCCTC | | |
| PDE5 | Sense: CTGTCTGATCTGGAAACAGC | 250 | 57 |
| | Antisense: GCAATCAGCAATGCAAGCGT | | |
| PDE8 | Sense: GGAGAACCAACTCCTTCCTGTG | 592 | 58 |
| | Antisense: AGGCATCCCATGCATCAAAC | | |




Figure 2. Effects of BCG and dexamethasone on total cells and differential cell counts in BALF of allergic rats. Rats were sensitized and challenged as described in Methods, and BALF was harvested 24 h post-last OVA challenge. Total inflammatory cell numbers in BALF were counted (A), and differential cell counts was performed on a minimum of 200 cells to classify eosinophils, neutrophils, lymphocytes and monocytes (B). Data are expressed as mean \pm SD. *: $p < 0.05$, **: $p < 0.01$, versus NS-challenged and vehicle-treated rats ($n=6$, NS-vehicle group); †: $p < 0.05$, ‡: $p < 0.01$ versus OVA-challenged and vehicle-treated rats ($n=6$, OVA-vehicle group).

The numbers of eosinophils, neutrophils, lymphocytes and monocytes/macrophages in the BALF of OVA-vehicle rats were increased 31-, 11-, 3- and 8-fold, respectively, as compared with those in NS-vehicle rats (e.g., the numbers of eosinophils, neutrophils, lymphocytes and monocytes/macrophages were 0.12×10^8 cells/L, 1.90×10^8 cells/L, 31.3×10^8 cells/L and 1.64×10^8 cells/L in NS-vehicle group) (Figure 2B). Treatment with BCG significantly decreased the number of eosinophil and neutrophil numbers in BALF as compared to allergic rats with vehicle treatment (Figure 2B). These results suggest that BCG inhibits inflammatory cells influx in lungs in response to allergen sensitization and challenge in rats.

Effect of BCG on Airway Inflammation

Lung tissue was harvested at 24 h post-last ovalbumin challenge. As shown in figure 3, OVA sensitization and challenge (Figure 3B) induced significant infiltration of inflammatory cells, especially eosinophils, into the peribronchiolar and perivascular tissues as compared with control rats (Figure 3A). Treatment with either BCG (Figure 3C) or dexamethasone (Figure 3D) significantly attenuated

OVA-induced eosinophil-rich leukocyte infiltration in lungs as compared with vehicle treatment.

Effect of BCG on Th1/Th2 level in Lung of Allergic Rats

It has been shown that the ratio of Th1/Th2 cytokines was decreased in asthma, and IFN- γ and IL-4 are critical cytokines secreted from Th1 and Th2 cells, respectively. Therefore, the levels of IL-4 and IFN- γ in the lungs of rats from the various groups were measured (Figure 4A and Figure 4B). OVA sensitization and challenge decreased IFN- γ and significantly increased IL-4 production in rat lung. Treatment with BCG (3×10^6 U/rat) or dexamethasone (1mg/kg) completely increased IFN- γ and suppressed the increased IL-4 production in response to allergen sensitization and challenge.

Effect of BCG on Allergen-induced Airway Hyperresponsiveness in Rats

In the rat model of allergic asthma, OVA sensitization caused a significant decrease in C_{dyn} whereas R_L was significantly increased in allergic rats as compared to control rats (Figure 5).




Figure 3. Effects of BCG and dexamethasone on allergen-induced inflammation cells infiltration in lungs. Rats were sensitized and challenged as described in Methods. Lung tissues were harvested 24 h after the last OVA challenge and immersed in 10% neutral formalin for 7 days. After tissues were paraffinized, 5 μ m sections were prepared and stained with hematoxylin-eosin for observation of cell infiltration under light microscope. Arrow: pointing to eosinophils




Figure 4. Effect of BCG and dexamethasone on IL-4 and IFN- γ levels in lungs of allergen challenged rats. Rats were sensitized and challenged as described in Methods, lung tissues were harvested 24 h after the last OVA challenge and used for determining the level of IL-4 (A) and IFN- γ (B) using a rat IL-4-specific ELISA kit and a rat IFN- γ -specific ELISA kit. Data are expressed as mean \pm SD. *: $p < 0.05$, **: $p < 0.01$, versus NS-challenged and vehicle-treated rats ($n=6$, NS-vehicle group); †: $p < 0.05$, ‡: $p < 0.01$ versus OVA-challenged and vehicle-treated rats ($n=6$, OVA-vehicle group).




Figure 5. Effects of BCG and dexamethasone on methacholine-induced change of lung resistance (R_L) and lung compliance (C_{dyn}) in allergen challenged rats. Rats were sensitized and challenged as described in Methods, 24 h post-last OVA challenge, R_L (A) and C_{dyn} (B) against aerosol methacholine was determined as described in Methods. Data are expressed as mean \pm SD. *: $p < 0.05$, **: $p < 0.01$, versus NS-challenged and vehicle-treated rats ($n=6$, NS-vehicle group); †: $p < 0.05$, ‡: $p < 0.01$ versus OVA-challenged and vehicle-treated rats ($n=6$, OVA-vehicle group).

Treatment with BCG significantly improved airway hyperresponsiveness including both C_{dyn} and R_L caused by sensitization and challenge at $8 \text{ g} \cdot \text{L}^{-1}$ MCh ($p < 0.05$), and this effect was almost the same as that of dexamethasone treatment (Figure 5). These results suggest that the improvement of airway hyperresponsiveness by BCG may be due to decreased

inflammatory response induced by OVA sensitization and challenge in lungs.

Effects of BCG on cAMP Level in Lung of Allergic Rats

It has been shown that decreased level of cAMP plays an important role in the pathogenesis of asthma, and BCG induced cAMP levels in bladder cancer cells.^{31,38,47} We hypothesize that BCG treatment could increase the cAMP level therefore attenuating airway inflammation and hyperresponsiveness. As expected, the level of cAMP was significantly decreased in lungs of allergen-induced asthmatic rats as compared to that in control animals (Figure 6). Administration of BCG increased the level of cAMP in lungs as compared to model group. Dexamethasone could also increase the level of cAMP in lungs, but its effect on cAMP was slightly weaker than that by BCG (Figure 6).




Figure 6. Effects of BCG and dexamethasone on cAMP production levels in lungs of allergic rats. Rats were sensitized and challenged as described in Methods, lung tissues were harvested 24 h after the last OVA challenge and used for determining the level of cAMP using a cAMP ELISA kit. Data are expressed as mean \pm SD. ** $p < 0.01$ versus NS-challenged and vehicle-treated rats ($n=6$); † $p < 0.05$ versus OVA-challenged and vehicle-treated rats ($n=6$).




Figure 7. Effects of BCG and dexamethasone on AC activity and cAMP-PDE activities in lungs of allergic rats. Rats were sensitized and challenged as described in Methods, lung tissues were harvested 24 h post-last OVA challenge and used for determination of AC activity by an AC reaction and cAMP ELISA kit (A), and for determination of cAMP-PDE activity by HPLC (B), respectively. Data are expressed as mean \pm SD. ** $p < 0.01$ versus NS-challenged and vehicle-treated rats ($n=6$); ‡ $p < 0.01$ versus OVA-challenged and vehicle-treated rats ($n=6$).

Effects of BCG on AC and PDE Activity in Lung of Allergic Rats

To investigate whether the change of cAMP level is related to the alteration of AC and/or PDEs activities. We determined the activities of AC and cAMP-PDE in lungs of control and allergen induced asthmatic rats. OVA sensitization and challenge significantly inhibited AC activity in lungs. However, treatment with BCG did not result in any obvious change in AC activity as compared to the vehicle treatment in allergen induced asthmatic rats. Interestingly, dexamethasone could significantly increase AC activity, and its effect on AC was stronger than BCG (Figure 7A).

Furthermore, pretreatment with BCG significantly attenuated the OVA-induced increase in cAMP-PDE activity in rat lungs, and its effect on cAMP-PDE activity was even more effective than dexamethasone (Figure 7B).

Effects of BCG on PDEs mRNA Expression in Lung of Allergic Rats

The mRNA levels of PDEs in lungs of control and allergic rats were determined in the absence or presence of BCG pretreatment. It was found that the mRNA levels of PDE1, PDE2, PDE3, PDE4A, PDE4B, PDE4C, PDE4D, PDE5, PDE7, PDE8, PDE9, PDE10, and PDE11 were expressed in lungs of control rats although the expression level of PDE10 mRNA was low (data not shown). OVA sensitization and challenge significantly increased the mRNA levels of PDE4A, PDE4C, PDE5, and PDE8 as compared to control rats (Figure 8A-D). Treatment with BCG significantly inhibited the mRNA expression level of PDE4A, 4C, 5 and 8 in lungs of allergen induced asthmatic rats as compared to that of model rats (Figure 8A-D). Similarly, dexamethasone showed significant effect on inhibition of PDE4A, 4C, 5 and 8 mRNA expression induced by allergen sensitization and challenge in lungs as compared to the model group (Figure 8A-D).




Figure 8. Effects of BCG and dexamethasone on PDEs mRNA expression in lungs of allergic rats. Rats were sensitized and challenged as described in Methods, lung tissues were harvested 24 h post-last OVA challenge and used for measurement of PDEs mRNA expression by RT-PCR. RNA isolation and cDNA synthesis were performed as described in Methods. The representative bands derived from PCR products of each PDE subtype are shown, and the intensity of PCR product-derived bands was quantified. The expression of PDE4A(A), 4C(B), 5(C), 8(D) were normalized to β -actin, and the results are expressed as means \pm SD from six rats. * $p < 0.05$, ** $p < 0.01$ versus NS-challenged and vehicle-treated rats ($n=6$); † $p < 0.05$, ‡ $p < 0.01$ versus OVA-challenged and vehicle-treated rats ($n=6$)

DISCUSSION

In recent decades, there has been a significant increase in the prevalence of asthma in various populations. Inhaled corticosteroids (ICS), short- and long-acting β_2 -adrenoceptor agonists are the current mainstay therapy for asthma. However, β_2 -adrenoceptor agonists only alleviate the symptoms. ICS are highly effective in suppressing airway inflammation, but they do not influence the natural

history of the disease even if treatment had been started early in childhood.^{6,7} Moreover, ICS can produce many side effects⁴⁸ and are largely ineffective in virus-induced exacerbations⁴⁹ and in those asthmatics who smoke.⁵⁰ Therefore, it is urgent to develop new drugs with more efficiency and less side effects in asthma treatment. BCG is originally known as a vaccine for tuberculosis, and regulates various cytokines production, as well as inhibit allergen-specific IgE production, OVA-induced eosinophilia, and goblet cell

development.^{30,31} Therefore, our rationale in this study was that BCG is beneficial to asthma treatment. It has been shown that a relatively high dose of BCG infection inhibits airway sensitivity, even after allergen sensitization.³⁹ Indeed, this was corroborated by our results showing decreased airway inflammatory response and airway hyperresponsiveness in BCG-treated and OVA-induced asthmatic model of SD rats. This was consistent with previous studies showing OVA-induced eosinophilia, goblet cell hyperplasia, high level of Th2 cytokines and airway hyperresponsiveness were inhibited by BCG.^{31,51-54}

It has been shown that the level of cAMP in lungs was decreased in asthmatics.^{38,47} We, and others, have found that some cAMP-inducing reagents, e.g. PDE inhibitors, theophylline, β_2 agonists, were effective in attenuating lung inflammatory response and improving lung function in patients with asthma and asthmatic model of animals.⁵⁵⁻⁵⁷ In the present study, we also found that treatment of BCG increased the level of cAMP in lungs induced by OVA, suggesting the protective effect of BCG on OVA-induced asthma in rats due to elevation of cAMP. This is consistent with the previous study showing an increased cAMP in human bladder cancer cells in response to BCG incubation.³⁶ It is well known that the level of cAMP is regulated by the AC and cAMP-PDE. Thus, we determined both enzymes activities in lungs of allergen-induced asthmatic rats in the absence or presence of BCG. We found that the AC activity was decreased, whereas an increased level of cAMP-PDE activity was observed in lungs of allergen-induced asthmatic rats. Furthermore, treatment with BCG decreased cAMP-PDE activity in lungs of allergic rats. It is interesting to note that the AC activity was inhibited in OVA-induced asthma rats, which was not affected by BCG. In this study, we also found that the effect of dexamethasone on cAMP was slightly weaker than BCG, whereas its effect on AC was stronger than BCG and its effect on cAMP-PDE activity was weaker than BCG. These results indicate that BCG and dexamethasone may have different mechanisms although they showed the same effect of increasing cAMP in lungs.

PDEs superfamily comprises 11 biochemically and pharmacologically distinct enzyme families (PDE1-11), which can hydrolyze cAMP and/or cGMP. It has been shown that PDE3, 4, 7, 8 are cAMP specific, PDE1, 5, 6, 9 are cGMP specific, and PDE2, 10, 11 can

hydrolyze both cAMP and cGMP. PDE inhibitors, especially PDE4 inhibitors, have been shown to attenuate airway inflammation and hyperresponsiveness in rodent models of asthma.^{58,59} Indeed, some PDE4 inhibitors, such as roflumilast and cilomilast, had successfully translated in phase II and III clinical trials and roflumilast (Daxas; Nycomed) had been granted marketing authorization by the European Commission for the maintenance treatment of severe chronic obstructive pulmonary disease, as an add-on to bronchodilator treatment in July 2010.^{60,61} We found that the OVA sensitization and challenge significantly increased the expression level of PDE4A, PDE4C, PDE4D, PDE5, PDE7 and PDE8 mRNA as compared to control rats (data not shown), which was consistent with previous studies indicating that PDEs activation play an important role in the pathogenesis and development of asthma.³⁸ Treatment of BCG inhibited PDE4A, PDE4C, PDE5 and PDE8 mRNA expressions, which may contribute to the decreased cAMP-PDE activity. The down-regulated PDEs by BCG attenuate cAMP degradation thereby increasing cAMP levels in lungs, which may be one of the mechanisms for attenuating airway inflammation and hyperresponsiveness in response to allergens exposure.

It has been shown that inflammation in asthma is correlated with the activation of PDE4A and PDE4B, and PDE4A is important in pathogenesis and development of asthma.^{62,63} Interestingly, PDE4C mRNA expression was increased in T-lymphocytes of asthma patients and in allergic rats although it appears to be more distal from other PDE4 subfamilies with certain key residues being disordered.^{37,64} Other PDE families, such as PDE5 and PDE8, have also been shown to play an important role in the pathogenesis of asthma, and their inhibitors have a potential in attenuating the progress of this disease.⁶⁵⁻⁶⁷ Indeed, the mRNA levels of all these PDE4A, PDE4C, PDE5 and PDE8 were significantly increased in asthmatic rats, which were lowered by BCG. Importantly, no effect of BCG on PDE4D that appears to mediate nausea and vomiting by PDE4 inhibitor was observed in this study. Hence, BCG could inhibit several PDEs with less side-effect than single PDE4 inhibitor, which could be more beneficial in asthma treatment. Furthermore, inhibition of other PDEs classes, along with PDE4 by BCG may be one of the effective avenues in controlling the progression of asthma because a mixed PDEs inhibitor provides more bronchodilator and bronchoprotective

effect in addition to the beneficial effects by PDE4 inhibitor.⁵⁵

In conclusion, BCG pretreatment significantly attenuated allergen-induced airway inflammation and hyperresponsiveness in rats. The mechanism underlying these findings is associated with the increased level of cAMP via inhibiting certain PDEs mRNA expression and cAMP-PDE activity in rat lung.

ACKNOWLEDGEMENTS

This project was partially supported by National Natural Science Foundation of China (No. 30873076) and Natural Science Foundation of Zhejiang Province (No. Z204198). We thank Prof Xi-mei Wu for manuscript revision.

REFERENCES

1. Thomas MS, Parolia A, Kundabala M, Vikram M. Asthma and oral health. *Aust Dent J* 2010; 55(2):128-33.
2. Fromer L. Managing asthma: an evidence-based approach to optimizing inhaled corticosteroid treatment. *South Med J* 2010; 103(10):1038-44.
3. Dozor AJ. The role of oxidative stress in the pathogenesis and treatment of asthma. *Ann N Y Acad Sci* 2010; 1203:133-7.
4. Fanta CH. Asthma. *N Engl J Med* 2009; 360(10):1002-14.
5. Kim SR, Rhee YK. Overlap Between Asthma and COPD: Where the Two Diseases Converge. *Allergy Asthma Immunol Res* 2010; 2(4):209-14.
6. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szeffler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006; 354(19):1985-97.
7. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. *N Engl J Med* 2006; 354(19):1998-2005.
8. Essayan DM. Cyclic nucleotide phosphodiesterases. *J Allergy Clin Immunol* 2001; 108(5):671-80.
9. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. *Trends Biochem Sci* 2010; 35(2):91-100.
10. Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. *Br J Pharmacol* 2010; 159(2):265-84.
11. Parker CW, Smith JW. Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma. I. Leukocyte responsiveness to -adrenergic agents. *J Clin Invest* 1973; 52(1):48-59.
12. Brown WM. Treating COPD with PDE 4 inhibitors. *Int J Chron Obstruct Pulmon Dis* 2007; 2(4):517-33.
13. Anderson GP. Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. *Clin Rev Allergy Immunol* 2006; 31(2-3):119-30.
14. Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. *Int J Chron Obstruct Pulmon Dis* 2008; 3(4):543-61.
15. Takeuchi M, Tatsumi Y, Kitaichi K, Baba K, Suzuki R, Shibata E, et al. Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor. *Biol Pharm Bull* 2002; 25(2):184-7.
16. Wang K, Shen HH, Huang HQ, Chen JC, Chen Z. Acetamide-45 inhibited hyperresponsiveness and airway inflammation in mice partly depending on phosphodiesterase activity suppression. *Acta Pharmacol Sin* 2008; 29(10):1195-201.
17. Yamaki K, Alam AH, Hossain MA, Taneda S, Yanagisawa R, Takano H, et al. Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice. *Scand J Immunol* 2005; 62(4):378-84.
18. Rousseau MC, Parent ME, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. *Pediatr Allergy Immunol* 2008; 19(5):438-48.
19. El-Zein M, Parent ME, Benedetti A, Rousseau MC. Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. *Int J Epidemiol* 2010; 39(2):469-86.
20. Miyake Y, Arakawa M, Tanaka K, Sasaki S, Ohya Y. Tuberculin reactivity and allergic disorders in schoolchildren, Okinawa, Japan. *Clin Exp Allergy* 2008; 38(3):486-92.
21. Ramsey CD, Celedon JC. The hygiene hypothesis and asthma. *Curr Opin Pulm Med* 2005; 11(1):14-20.
22. Alyasin S, Katibeh P, Asadi S. The relationship between tuberculin response, BCG vaccine scar and asthma. *Iran J Allergy Asthma Immunol* 2009; 8(4):205-10.
23. Martignon G, Oryszczyn MP, Annesi-Maesano I. Does childhood immunization against infectious diseases

- protect from the development of atopic disease? *Pediatr Allergy Immunol* 2005; 16(3):193-200.
24. Soysal A, Bahceciler N, Barlan I, Bakir M. Lack of an inverse association between tuberculosis infection and atopy: by T-cell-based immune assay (RD1-ELISpot). *Pediatr Allergy Immunol* 2008; 19(8):709-15.
 25. Shen HH, Zhang GS, Wang PL. Mycobacterium bovis-Bacillus Calmette-Guerin and asthma. *Chin Med J (Engl)* 2005; 118(11):942-7.
 26. Han ER, Choi IS, Eom SH, Kim HJ. Preventive effects of mycobacteria and their culture supernatants against asthma development in BALB/c mice. *Allergy Asthma Immunol Res*; 2010; 2(1):34-40.
 27. Li J, Luo DF, Li SY, Sun BQ, Zhong NS. Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study. *Chin Med J (Engl)* 2005; 118(19):1595-603.
 28. Sartono E, Lisse IM, Terveer EM, van de Sande PJ, Whittle H, Fisker AB, et al. Oral polio vaccine influences the immune response to BCG vaccination. A natural experiment. *PLoS One* 2010; 5(5):10328.
 29. Zhang GS, Shen HH. [The preventive effect of bacillus Calmette-Guerin vaccination in early life on airway inflammation and mucus production in a murine model of asthma]. *Zhonghua Jie He He Hu Xi Za Zhi* 2005; 28(1):17-21.
 30. Koh YI, Choi IS, Kim WY, Lee HC, Lee J. Effects of BCG infection on Schultz-Dale reaction, allergen-specific IgE levels, and Th2 immune response in sensitized rats. *Korean J Intern Med* 2001; 16(3):180-6.
 31. Yang X, Wang S, Fan Y, Zhu L. Systemic mycobacterial infection inhibits antigen-specific immunoglobulin E production, bronchial mucus production and eosinophilic inflammation induced by allergen. *Immunology* 1999; 98(3):329-37.
 32. Choi IS, Lin XH, Koh YA, Koh YI, Lee HC. Strain-dependent suppressive effects of BCG vaccination on asthmatic reactions in BALB/c mice. *Ann Allergy Asthma Immunol* 2005; 95(6):571-8.
 33. Li R, Liu EM, Yang XQ, Wang LJ. [Combined effects of neonatal Bacillus Calmette-Guerin vaccination and respiratory syncytial infection on experimental asthma in mice]. *Zhonghua Er Ke Za Zhi* 2006; 44(6):420-4.
 34. Li C, Xu Y, Zhang Z, Yang D, Liu X, Xiong W. An experimental study of the effect of bacille calmette-guerin vaccine on the production of a rat asthmatic model and its relation with gamma delta T cells. *Zhonghua Jie He He Hu Xi Za Zhi* 2002; 25(3):162-5.
 35. Lagranderie M, Abolhassani M, Vanoirbeek JA, Lima C, Balazuc AM, Vargaftig BB, et al. Mycobacterium bovis bacillus Calmette-Guerin killed by extended freeze-drying targets plasmacytoid dendritic cells to regulate lung inflammation. *J Immunol*; 2010; 184(2):1062-70.
 36. Zhang Y, Mahendran R, Yap LL, Esuvaranathan K, Khoo HE. The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells. *Biochem Pharmacol* 2002; 63(2):273-82.
 37. Tang HF, Chen JQ, Xie QM, Zheng XY, Zhu YL, Adcock I, et al. The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats. *Biochim Biophys Acta* 2006; 1762(5):525-32.
 38. Tang HF, Song YH, Chen JC, Chen JQ, Wang P. Upregulation of phosphodiesterase-4 in the lung of allergic rats. *Am J Respir Crit Care Med* 2005; 171(8):823-8.
 39. Koh YI, Choi IS, Park SC, Kang KW. BCG infection during pre-sensitization or even post-sensitization inhibits airway sensitivity in an animal model of allergic asthma. *J Korean Med Sci* 2000; 15(3):265-72.
 40. Sergienko DV, Boklag SP. [Bronchial asthma: characteristics of modern diagnostics]. *Lik Sprava* 2010; (1-2):31-9.
 41. Xie QM, Chen JQ, Shen WH, Yang QH, Bian RL. Effects of cyclosporin A by aerosol on airway hyperresponsiveness and inflammation in guinea pigs. *Acta Pharmacol Sin* 2002; 23(3):243-7.
 42. Leon D, Albasanz JL, Ruiz MA, Martin M. Chronic caffeine or theophylline intake during pregnancy inhibits A1 receptor function in the rat brain. *Neuroscience* 2005; 131(2):481-9.
 43. Kostic MM, Erdogan S, Rena G, Borchert G, Hoch B, Bartel S, et al. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. *J Mol Cell Cardiol* 1997; 29(11):3135-46.
 44. Naro F, Sette C, Vicini E, De Arcangelis V, Grange M, Conti M, et al. Involvement of type 4 cAMP-phosphodiesterase in the myogenic differentiation of L6 cells. *Mol Biol Cell* 1999; 10(12):4355-67.
 45. Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. *Am J Physiol Lung Cell Mol Physiol* 2005; 288(1):L103-15.
 46. Witwicka H, Kobialka M, Siednienko J, Mitkiewicz M, Gorczyca WA. Expression and activity of cGMP-dependent phosphodiesterases is up-regulated by

- lipopolysaccharide (LPS) in rat peritoneal macrophages. *Biochim Biophys Acta* 2007; 1773(2):209-18.
47. Parker CW, Huber MG, Baumann ML. Alterations in cyclic AMP metabolism in human bronchial asthma. 3. Leukocyte and lymphocyte responses to steroids. *J Clin Invest* 1973; 52(6):1342-8.
 48. Lehmann S, Ott H. Glucocorticoid hypersensitivity as a rare but potentially fatal side effect of paediatric asthma treatment: a case report. *J Med Case Reports* 2008; 2:186.
 49. Harrison TW, Osborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. *Lancet* 2004; 363(9405):271-5.
 50. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. *Am J Respir Crit Care Med* 2003; 168(11):1308-11.
 51. Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G. Infection of mice with *Mycobacterium bovis*-*Bacillus Calmette-Guerin* (BCG) suppresses allergen-induced airway eosinophilia. *J Exp Med* 1998; 187(4):561-9.
 52. Major T, Wohlleben G, Reibetanz B, Erb KJ. Application of heat killed *Mycobacterium bovis*-BCG into the lung inhibits the development of allergen-induced Th2 responses. *Vaccine* 2002; 20(11-12):1532-40.
 53. Nahori MA, Lagranderie M, Lefort J, Thouron F, Joseph D, Winter N, et al. Effects of *Mycobacterium bovis* BCG on the development of allergic inflammation and bronchial hyperresponsiveness in hyper-IgE BP2 mice vaccinated as newborns. *Vaccine* 2001; 19(11-12):1484-95.
 54. Shen H, Huang H, Wang J, Ye S, Li W, Wang K, et al. Neonatal vaccination with *Bacillus Calmette-Guerin* elicits long-term protection in mouse-allergic responses. *Allergy* 2008; 63(5):555-63.
 55. Fan Chung K. Phosphodiesterase inhibitors in airways disease. *Eur J Pharmacol* 2006; 533(1-3):110-7.
 56. Moon HG, Kim YS, Choi JP, Choi DS, Yoon CM, Jeon SG, et al. Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma. *Exp Mol Med* 2010; 42(1):47-60.
 57. Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, Barnes PJ, et al. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. *Am J Physiol Lung Cell Mol Physiol* 2008; 295(3):L505-14.
 58. Deng YM, Xie QM, Tang HF, Sun JG, Deng JF, Chen JQ, et al. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. *Eur J Pharmacol* 2006; 547(1-3):125-35.
 59. Sun JG, Deng YM, Wu X, Tang HF, Deng JF, Chen JQ, et al. Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma. *Life Sci* 2006; 79(22):2077-85.
 60. Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. Roflumilast. *Nat Rev Drug Discov* 2010; 9(10):761-2.
 61. Spina D. PDE4 inhibitors: current status. *Br J Pharmacol* 2008; 155(3):308-15.
 62. Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. *Biochem J* 2007; 408(2):193-201.
 63. Woyda K, Koebrich S, Reiss I, Rudloff S, Pullamsetti SS, Ruhlmann A, et al. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. *Eur Respir J* 2009; 33(4):861-70.
 64. Jeong HC, Lee SY, Lee EJ, Jung KH, Kang EH, Kim JH, et al. Proteomic analysis of peripheral T-lymphocytes in patients with asthma. *Chest* 2007; 132(2):489-96.
 65. Al Qadi-Nassar B, Bichon-Laurent F, Portet K, Tramini P, Arnoux B, Michel A. Effects of L-arginine and phosphodiesterase-5 inhibitor, sildenafil, on inflammation and airway responsiveness of sensitized BP2 mice. *Fundam Clin Pharmacol* 2007; 21(6):611-20.
 66. Dong H, Osmanova V, Epstein PM, Brocke S. Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. *Biochem Biophys Res Commun* 2006; 345(2):713-9.
 67. Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. *Am J Respir Crit Care Med* 2004; 169(2):227-34.